• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Veru Inc.

    12/17/25 12:27:44 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERU alert in real time by email
    S-8 1 veru20251209_s8.htm FORM S-8 veru20251209_s8.htm

    As filed with the Securities and Exchange Commission on December 17, 2025

    Registration No. 333 -_______

     



    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     


     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     


     

    VERU INC.

    (Exact name of registrant as specified in its charter)

     


    Wisconsin

    39-1144397

    (State of Incorporation)

    (I.R.S. Employer

     

    Identification No.)

     

    2916 North Miami Avenue, Suite 1000

    Miami, Florida 33127

    (Address of principal executive offices) (Zip Code)

     


     

    VERU INC.

    2018 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     


     

    Mitchell S. Steiner, M.D.

    Chairman, President and Chief Executive Officer

    2916 North Miami Avenue, Suite 1000

    Miami, Florida 33127

    (305) 509-6897

    (Name and address of agent for service and telephone number, including area code, of agent for service)

     


     

    Copy to:

     

    Benjamin G. Lombard, Esq.

    Reinhart Boerner Van Deuren s.c.

    1000 North Water Street

    Suite 1700

    Milwaukee, Wisconsin 53202

    (414) 298-1000

     


     

    Indicate by check mark whether the restraint is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

     

     

    Large accelerated filer ☐

    Accelerated filer  ☐

     

    Non-accelerated filer   ☒

    Smaller reporting company  ☒

       

    Emerging growth company  ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period or comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   ☐

     

     

     
     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

     

    This Registration Statement has been filed to register 750,000 additional shares of the Registrant's Common Stock made available under the Veru Inc. 2018 Equity Incentive Plan (the “2018 Plan”) by reason of an amendment thereto approved by the shareholders of the Registrant. Pursuant to General Instruction E to Form S-8, the contents of the Registrant's earlier Registration Statement on Form S-8 (Registration No. 333-228789) effective December 13, 2018 are incorporated by reference and made a part hereof.

     

    The shares of the Registrant’s Common Stock authorized for issuance under the 2018 registered on Form S-8 have been adjusted as referenced herein to reflect the Registrant’s 1-for-10 reverse stock split of the authorized and issued and outstanding shares of Common Stock (the “Reverse Stock Split”) which became effective on August 8, 2025. As a result of the Reverse Stock Split, every 10 shares of Common Stock issued and outstanding were converted into one share of Common Stock along with the number of shares to be awarded under the 2018 Plan. The additional number of shares approved by shareholders under the 2018 Plan was 7,500,000, which has been adjusted to 750,000 to give effect to the Reverse Stock Split.

     

    Item 8.

    Exhibits.

     

    Exhibit

    Number

     

    Description

    4.1

     

    Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant's Registration Statement on Form SB-2 (File No. 333-89273) filed with the Commission on October 19, 1999).

    4.2

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 27,000,000 shares (incorporated by reference to Exhibit 3.2 to the registrant's Registration Statement on Form SB-2 (File No. 333-46314) filed with the Commission on September 21, 2000).

    4.3

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 35,500,000 shares (incorporated by reference to Exhibit 3.3 to the registrant's Registration Statement on Form SB-2 (File No. 333-99285) filed with the Commission on September 6, 2002).

    4.4

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 38,500,000 shares (incorporated by reference to Exhibit 3.4 to the registrant's Quarterly Report on Form 10-QSB (File No. 1-13602) filed with the Commission on May 15, 2003).

    4.5

     

    Articles of Amendment to Amended and Restated Articles of Incorporation designating the terms and preferences for the Class A Preferred Stock – Series 3 (incorporated by reference to Exhibit 3.5 to the registrant's Quarterly Report on Form 10-QSB (File No. 1-13602) filed with the Commission on May 17, 2004).

    4.6

     

    Articles of Amendment to Amended and Restated Articles of Incorporation designating the terms and preferences for the Class A Preferred Stock – Series 4 (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8‑K (File No. 1-13602) filed with the Commission on November 2, 2016).

    4.7

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 77,000,000 shares (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8‑K (File No. 1-13602) filed with the Commission on August 1, 2017).

    4.8

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 154,000,000 shares (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 1-13602) filed with the Commission on March 29, 2019).

     

    2

     

     

    Exhibit

    Number

      Description
    4.9

     

    Articles of Amendment to Amended and Restated Articles of Incorporation increasing the number of authorized shares of common stock to 308,000,000 shares (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 1-13602) filed with the Commission on July 28, 2023).

    4.10

     

    Articles of Amendment to Amended and Restated Articles of Incorporation of Veru Inc. to effect the Reverse Stock Split (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 1-13602) filed with the Commission on August 12, 2025).

    4.11

     

    Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K (File No. 1-13602) filed with the Commission on May 4, 2018).

    5.1

     

    Opinion of Reinhart Boerner Van Deuren s.c. *

    23.1

     

    Consent of Cherry Bekaert LLP. *

    23.2

     

    Consent of Reinhart Boerner Van Deuren s.c. (included in Exhibit 5.1 to this Registration Statement). *

    24.1

     

    Power of Attorney (included on the signature page to this Registration Statement).

    99.1

     

    Veru Inc. 2018 Equity Incentive Plan (as amended and restated effective March 13, 2025) (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 1-13602) filed with the Commission on March 14, 2025).

    107

     

    Filing Fee Table. *

     

    *Filed herewith.

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, State of Florida on December 17, 2025.

     

     

    VERU INC.

     

     

     

     

     

     

     

     

     

     

     

     

    BY

     

    /s/ Mitchell S. Steiner

     

     

     

     

    Mitchell S. Steiner, Chairman, President

     

     

     

     

    and Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby appoints Mitchell S. Steiner and Michele Greco, and each of them individually, as his or her true and lawful attorney‑in‑fact and agent, with power to act with or without the other and with full power of substitution and resubstitution, in any and all capacities, to sign any or all amendments (including post‑effective amendments) to the Registration Statement and file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys‑in‑fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys‑in‑fact and agents, or their substitutes, may lawfully cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

    /s/ Mitchell S. Steiner

     

    Chairman, President, Chief Executive Officer and Director

     

    December 17, 2025

    Mitchell S. Steiner   (Principal Executive Officer)    
             

    /s/ Harry Fisch

     

    Vice Chairman of the Board and Director

     

    December 17, 2025

    Harry Fisch        
             

    /s/ Grace S. Hyun

     

    Director

     

    December 17, 2025

    Grace S. Hyun        
             

    /s/ Lucy Lu

     

    Director

     

    December 17, 2025

    Lucy Lu        
             

    /s/ Michael L. Rankowitz

     

    Director

     

    December 17, 2025

    Michael L. Rankowitz        
             

    /s/ Loren M. Katzovitz

     

    Director

     

    December 17, 2025

    Loren M. Katzovitz        
             
    /s/ Michele Greco   Chief Financial Officer and Chief Administrative Officer   December 17, 2025

    Michele Greco

     

    (Principal Financial and Accounting Officer)

     

     

     

    4
    Get the next $VERU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERU

    DatePrice TargetRatingAnalyst
    12/18/2025$25.00Buy
    Canaccord Genuity
    5/14/2024$5.00Buy
    B. Riley Securities
    3/28/2024$3.00Outperform
    Raymond James
    6/7/2023$1.00Underperform → Hold
    Jefferies
    More analyst ratings

    $VERU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/28/24 5:04:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/24/24 6:57:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

    -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements -- -- Company plans to initiate Phase 2 PLATEAU clinical study in calendar Q1 2026 -- -- Post fiscal year end, company completed public offering for net proceeds of approximately $23.4 million -- -- Company to host conference call and webcast today at 8:00 a.m. ET -- MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceu

    12/17/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal Year 2025 Financial Results on December 17th

    MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

    12/10/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Veru with a new price target

    B. Riley Securities initiated coverage of Veru with a rating of Buy and set a new price target of $5.00

    5/14/24 8:03:44 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Veru with a new price target

    Raymond James initiated coverage of Veru with a rating of Outperform and set a new price target of $3.00

    3/28/24 7:50:24 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Barnette K Gary

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:29:58 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Rankowitz Michael L

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:19:11 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Katzovitz Loren Mark

    4 - VERU INC. (0000863894) (Issuer)

    12/9/25 12:10:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    SEC Filings

    View All

    SEC Form DEFA14A filed by Veru Inc.

    DEFA14A - VERU INC. (0000863894) (Filer)

    1/28/26 4:07:48 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Veru Inc.

    DEF 14A - VERU INC. (0000863894) (Filer)

    1/28/26 4:06:14 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Veru Inc.

    S-8 - VERU INC. (0000863894) (Filer)

    12/17/25 12:27:44 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Financials

    Live finance-specific insights

    View All

    Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

    MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 first quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru I

    2/4/26 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru to Report Fiscal Year 2025 Financial Results on December 17th

    MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Wednesday, December 17, 2025, at 8:00 a.m. ET to discuss its fiscal year 2025 financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of the Company's website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.

    12/10/25 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

    --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-- --Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation-- --Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study-- --Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserv

    8/12/25 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Leadership Updates

    Live Leadership Updates

    View All

    Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board

    MIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory Board (SAB) to join David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, who is Chairman of the SAB. "We are pleased to share that Dr. Erik Swenson and

    6/1/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board

    MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced the appointment of David D. Ho, M.D., a trailblazer of infectious disease viral research and therapeutic development, as Chairman of its Scientific Advisory Board (SAB). "Today's appointment of Dr. Ho as Chairman of Veru's SAB illustrates our commitment to building a team of scientific experts to support our goal of developing and delivering life-saving therapies to patients with COVID-19 and other viral ARDS-related diseases," said Mitchell Steiner, M.D., Chairman, Presi

    1/10/23 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients

    MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru's Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhan

    8/19/22 8:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VERU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/12/24 9:34:37 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veru Inc.

    SC 13G/A - VERU INC. (0000863894) (Subject)

    11/4/24 4:19:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Veru Inc.

    SC 13G - VERU INC. (0000863894) (Subject)

    4/24/24 4:16:01 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care